After working in Wall Street for over two decades, Paul Mampilly signed on to Banyan Hill Publishing in 2016 to start investment newsletter. Through his startup, Profits Unlimited, Paul focuses on helping average Americans to generate wealth from technology, growth investing, special opportunities and small-cap stocks. He was inspired to leave Wall Street after realizing that the entities products only benefited a limited number of people.
He ventured into newsletter publishing to ensure that people could access professional help on investing. The already successful venture undertakes vigorous research on stocks before recommending them to clients. He keeps track of all the stocks for purposes of acquiring new information concerning the stocks’ impact on the market. Paul relies on other experts’ opinions on his stock picks to get a clear understanding of the same before recommending such stocks to clients.
About Paul Mampilly
Initially, Paul Mampilly worked as an assistant portfolio manager for Bankers Trust on Wall Street. He rose through the ranks to serve renowned companies such as Deutsche Bank, Kinetics Asset Management and ING. While working for Kinetics, Mampilly helped the company’s hedge fund to enhance their assets to $25 billion, earning the company a title as world’s best hedge fund with annual average returns of 26 percent. Paul Mampilly also participated in the investment competition organized by the Templeton Foundation where he emerged a winner after generating returns of 76 percent from a $50 million investment. Within a year, Profits Unlimited has generated over 40 percent in profits.
Paul is also the founder of Capuchin Consulting where he offers investment guidance to professional investors. The successful investor is also an accomplished author and analyst. He worked for Stansberry Research, Common Sense Publishing and Agora Financial where he rendered his services as an investment director. During his tenure at Agora Financial where he managed FDA Trader fund, he managed to generate over $6 million in sales. This way, the company the major investment source for investors in biotech. Paul Mampilly holds an MBA in finance from Fordham Gabelli School of Business and a BBA in finance and accounting from Montclair State University. He also studied financial engineering and economics at the New York University Polytechnic School of Engineering and the City University of New York, Hunter College respectively.